Semnur Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the period ended September 30, 2026.
Key Highlights
- Share count: As of November 4, 2026, the registrant had 217,709,142 shares of common stock outstanding.
- OTCQB trading: The company's securities have traded on the OTCQB marketplace under the symbols "SMNR" and "SMNRW" since September 23, 2025, following suspension from The Nasdaq Capital Market on April 16, 2025.
- Business combination completed: The registrant consummated a business combination with Legacy Semnur Pharmaceuticals on September 22, 2025, effected through the merger of a wholly owned subsidiary with Legacy Semnur.
- Name change: In connection with the business combination, the registrant changed its name from Denali Capital Acquisition Corp. to Semnur Pharmaceuticals, Inc.
- Warrant terms: Outstanding warrants entitle holders to purchase one share of common stock each at an exercise price of $11.50 per share.
- Filer status: The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, and is not a shell company.
Semnur Pharmaceuticals Reports First Full Post-Combination Quarter on OTCQB
Semnur Pharmaceuticals, Inc. (OTC:SMNR), formerly Denali Capital Acquisition Corp., submitted its quarterly report for the period ended September 30, 2026, disclosing operational and structural details following its business combination completed in September 2025. According to the filing, the company had 217,709,142 shares of common stock outstanding as of November 4, 2026, the date the report was filed with the SEC under Commission File Number 001-41351.
The filing describes how the business combination was consummated on September 22, 2025, pursuant to an agreement and plan of merger dated August 30, 2024, as subsequently amended on April 16, 2025 and July 22, 2025. Under the terms of the merger agreement, Denali Merger Sub Inc., a wholly owned subsidiary of Denali, merged with and into Legacy Semnur Pharmaceuticals, with Legacy Semnur surviving as a wholly owned subsidiary of the renamed parent. The company characterizes this transaction as a "reverse recapitalization" for accounting purposes.
The registrant's securities were suspended from trading on The Nasdaq Capital Market on April 16, 2025, and began trading on the OTCQB marketplace the following day under the symbols "DNQAF," "DNQWF," and "DNQUF," according to the filing. Following the domestication and business combination, trading on OTCQB shifted to the current symbols "SMNR" and "SMNRW" beginning September 23, 2025. The filing notes the company is a Delaware corporation with its principal offices located at 960 San Antonio Road, Palo Alto, CA 94303. The filing contains forward-looking statements, which the company cautions are subject to risks and uncertainties described in its Risk Factors section and should not be relied upon as representing views as of any subsequent date.
What Was Disclosed
Semnur Pharmaceuticals filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 217,709,142 shares outstanding, its OTCQB trading status under "SMNR" and "SMNRW," and details of its September 2025 business combination with Legacy Semnur.




Please wait processing your request...